demonstrates that smart, hierarchical material design —where each component plays a distinct functional role—can finally break the long‑standing trade‑offs of lithium‑ion technology. By simultaneously delivering high energy , ultra‑fast power , robust safety , and century‑scale durability , HMN‑372 positions itself as the cornerstone of the next generation of electrified society.
| Indication | Current Standard of Care | Unmet Need | HMN‑372’s Potential Role | |------------|--------------------------|------------|--------------------------| | | Cholinesterase inhibitors, NMDA‑antagonist, aducanumab/lecanemab (amyloid‑targeting antibodies) | Disease‑modifying agents that address non‑amyloid pathology | Early disease‑modifying effect via neuro‑inflammation reduction; oral, BBB‑penetrant | | Parkinson’s disease | Levodopa, dopamine agonists, MAO‑B inhibitors | Progression‑slowing, non‑motor symptom control | May attenuate α‑synuclein‑induced microglial activation; preliminary motor benefit | | Treatment‑resistant depression | SSRIs, SNRIs, ketamine/esketamine, psychotherapy | High relapse rates, limited anti‑inflammatory options | Targeting IL‑1β/IL‑18 axis could normalize neuro‑immune cross‑talk implicated in depressive phenotypes | | Chronic neuropathic pain | Gabapentinoids, opioids, duloxetine | Opioid crisis, inadequate efficacy | Pre‑clinical models show reversal of pain hypersensitivity via microglial inhibition | HMN-372